The Withdrawal of Drugs for Commercial Reasons
Author:
- 1 December 2014
- journal article
- viewpoint
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 174 (12) , 1887-1888
Abstract
This Viewpoint describe the case of the commercial withdrawal of tositumomab as a cautionary tale of the weaknesses in our current drug-approval system.Keywords
This publication has 5 references indexed in Scilit:
- Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 TrialJournal of Clinical Oncology, 2013
- Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016Journal of Clinical Oncology, 2013
- Market withdrawal of new molecular entities approved in the United States from 1980 to 2009Pharmacoepidemiology and Drug Safety, 2011
- New active substances authorized in the United Kingdom between 1972 and 1994British Journal of Clinical Pharmacology, 1998
- Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) AntibodyNew England Journal of Medicine, 1993